Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03659136
Recruitment Status : Completed
First Posted : September 6, 2018
Last Update Posted : May 17, 2022
Information provided by (Responsible Party):
Boehringer Ingelheim

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : August 30, 2021
Actual Study Completion Date : April 26, 2022
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 10, 2022